Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) | MicrobiomeTrials
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-05-11Est. Completion: 2028-01-03
Enrollment target: 300 participants
Locations
Cahaba Research, Inc., Pelham, Alabama, United States
Arizona Clinical Trials, Chandler, Arizona, United States
Epic Medical Research - Sun City, Sun City, Arizona, United States
Clinical Research Institute of Arizona LLC, Sun City West, Arizona, United States
Peninsula Research Associates, Chula Vista, California, United States
Desert Oasis Healthcare Medical Group, Palm Springs, California, United States
Inland Empire Liver Foundation, Rialto, California, United States
Apex Clinical Research, San Diego, California, United States
Southern California Clinical Research, Santa Ana, California, United States
University of Florida Department of Medicine, Gainesville, Florida, United States
Aga Clinical Trials, Hialeah, Florida, United States
South Florida Clinical Research, Margate, Florida, United States
New Horizon Research Center, Miami, Florida, United States
Research Institute of South Florida, Miami, Florida, United States
Adult Medicine of Lake County, Mt. Dora, Florida, United States
Other microbiome trials you might be interested in